Asia-Pacific Antimicrobial Resistance Gaps

WHO finds stronger AMR action plans across 28 APAC countries, but financing and prevention infrastructure remain weak.

AMR Plans Strong, Financing Weak

APAC: Antimicrobial resistance (AMR) continues to pose a grave threat across Asia-Pacific, with WHO reporting that while 28 countries have strengthened national action plans, financing and infection-prevention infrastructure remain inadequate.

Why Is AMR So Critical?

AMR undermines the effectiveness of antibiotics, making common infections harder to treat. In Asia, high rates of antibiotic misuse in hospitals and agriculture have accelerated resistance. “Without sustained investment, AMR could reverse decades of medical progress,” warned Dr. Sunita Sharma, WHO’s regional AMR coordinator.

What Does This Mean for Healthcare Systems?

Countries like Japan and Singapore have advanced surveillance systems, but many lower-income nations lack laboratory capacity and funding. This disparity creates regional vulnerabilities, as resistant pathogens do not respect borders. WHO has urged governments to prioritise financing for infection control, sanitation, and stewardship programs.

Experts call for cross-border cooperation, innovation in diagnostics, and incentives for pharmaceutical companies to develop new antibiotics. Without urgent action, AMR could become Asia’s next silent pandemic.

Source: WHO Asia-Pacific AMR Report, October 2026.